| 臺大學術典藏 |
2020-05-25T02:45:22Z |
Cranial Irradiation for Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors
|
Lee J.-H;Chen H.-Y;Feng-Ming Hsu;Chen J.-S;Liao W.-Y;Shih J.-Y;Yu C.-J;Chen K.-Y;Tsai T.-H;Yang J.C.-H.; Lee J.-H; Chen H.-Y; Feng-Ming Hsu; Chen J.-S; Liao W.-Y; Shih J.-Y; Yu C.-J; Chen K.-Y; Tsai T.-H; Yang J.C.-H. |
| 臺大學術典藏 |
2020-05-25T01:33:01Z |
Development of renal cysts after crizotinib treatment in advanced ALK-positive non-small-cell lung cancer
|
YEN-TING LIN; Wang Y.-F.; Yang J.C.-H.; Yu C.-J.; Wu S.-G.; Shih J.-Y.; Yang P.-C. |
| 臺大學術典藏 |
2020-05-25T01:33:00Z |
Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non–Small-Cell Lung Cancer: Analysis and Literature Review
|
YEN-TING LIN; Yu C.-J.; Yang J.C.-H.; Shih J.-Y. |
| 臺大學術典藏 |
2020-05-25T01:32:59Z |
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-sensitive Exon 19 Insertion and Exon 20 Insertion in Patients With Advanced Non–Small-cell Lung Cancer
|
YEN-TING LIN; Liu Y.-N.; Wu S.-G.; Yang J.C.-H.; Shih J.-Y. |
| 臺大學術典藏 |
2020-05-25T01:32:58Z |
Validation of immunohistochemistry for the detection of BRAF V600E-mutated lung adenocarcinomas
|
Gow C.-H.; Hsieh M.-S.; YEN-TING LIN; Liu Y.-N.; Shih J.-Y. |
| 臺大學術典藏 |
2020-05-25T01:32:58Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
YEN-TING LIN; Chen J.-S.; Liao W.-Y.; Ho C.-C.; Hsu C.-L.; Yang C.-Y.; Chen K.-Y.; Lee J.-H.; Lin Z.-Z.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2020-05-25T01:32:56Z |
Complex EGFR mutations with secondary T790M mutation confer shorter osimertinib progression-free survival and overall survival in advanced non-small cell lung cancer
|
Shih J.-Y.;Yu C.-J.;Liu Y.-N.;Wu S.-G.;Tsai T.-H.;YEN-TING LIN; YEN-TING LIN; Tsai T.-H.; Wu S.-G.; Liu Y.-N.; Yu C.-J.; Shih J.-Y. |
| 臺大學術典藏 |
2020-05-20T05:11:45Z |
Development of renal cysts after crizotinib treatment in advanced ALK-positive non-small-cell lung cancer
|
Wu S.-G.; Shih J.-Y.; Yang P.-C.; Yu C.-J.; Yang J.C.-H.; Wang Y.-F.; YEN-TING LIN; Yang P.-C.;Shih J.-Y.;Wu S.-G.;Yu C.-J.;Yang J.C.-H.;Wang Y.-F.;YEN-TING LIN |
| 臺大學術典藏 |
2020-05-20T05:11:44Z |
Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non�VSmall-Cell Lung Cancer: Analysis and Literature Review
|
Yang J.C.-H.; Yu C.-J.; YEN-TING LIN; Shih J.-Y.;Yang J.C.-H.;Yu C.-J.;YEN-TING LIN; Shih J.-Y. |
| 臺大學術典藏 |
2020-05-20T05:11:43Z |
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-sensitive Exon 19 Insertion and Exon 20 Insertion in Patients With Advanced Non�VSmall-cell Lung Cancer
|
Shih J.-Y.;Yang J.C.-H.;Wu S.-G.;Liu Y.-N.;YEN-TING LIN; YEN-TING LIN; Liu Y.-N.; Wu S.-G.; Yang J.C.-H.; Shih J.-Y. |
| 臺大學術典藏 |
2020-05-20T05:11:42Z |
Validation of immunohistochemistry for the detection of BRAF V600E-mutated lung adenocarcinomas
|
Shih J.-Y.;Liu Y.-N.;YEN-TING LIN;Hsieh M.-S.;Gow C.-H.; Gow C.-H.; Hsieh M.-S.; YEN-TING LIN; Liu Y.-N.; Shih J.-Y. |
| 臺大學術典藏 |
2020-05-20T05:11:42Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Yu C.-J.;Yang J.C.-H.;Shih J.-Y.;Lin Z.-Z.;Lee J.-H.;Chen K.-Y.;Yang C.-Y.;Hsu C.-L.;Ho C.-C.;Liao W.-Y.;Chen J.-S.;YEN-TING LIN; YEN-TING LIN; Chen J.-S.; Liao W.-Y.; Ho C.-C.; Hsu C.-L.; Yang C.-Y.; Chen K.-Y.; Lee J.-H.; Lin Z.-Z.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2020-05-20T05:11:42Z |
The Impact of Clinical Factors, ALK Fusion Variants, and BIM Polymorphism on Crizotinib-Treated Advanced EML4�VALK Rearranged Non-small Cell Lung Cancer
|
Shih J.-Y.;Liu Y.-N.;YEN-TING LIN; YEN-TING LIN; Liu Y.-N.; Shih J.-Y. |
| 臺大學術典藏 |
2020-05-20T05:11:41Z |
Complex EGFR mutations with secondary T790M mutation confer shorter osimertinib progression-free survival and overall survival in advanced non-small cell lung cancer
|
Shih J.-Y.; Yu C.-J.; Liu Y.-N.; Wu S.-G.; Tsai T.-H.; YEN-TING LIN; Shih J.-Y.;Yu C.-J.;Liu Y.-N.;Wu S.-G.;Tsai T.-H.;YEN-TING LIN |
| 臺大學術典藏 |
2020-04-27T08:45:08Z |
Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgery
|
Yang W.-C.;Xiao F.;Shih J.-Y.;Ho C.-C.;Chen Y.-F.;Tseng H.-M.;Chen K.-Y.;Liao W.-Y.;Yu C.-J.;Yang J.C.-H.;Kuo S.-H.;Chia-Hsien Cheng;Yang P.-C.;Hsu F.-M.; Yang W.-C.; Xiao F.; Shih J.-Y.; Ho C.-C.; Chen Y.-F.; Tseng H.-M.; Chen K.-Y.; Liao W.-Y.; Yu C.-J.; Yang J.C.-H.; Kuo S.-H.; CHIA-HSIEN CHENG; Yang P.-C.; Hsu F.-M. |
| 臺大學術典藏 |
2020-04-16T02:34:34Z |
Identification of a novel biomarker, SEMA5A, for non-small cell lung carcinoma in nonsmoking women
|
Lu, T.-P.;Tsai, M.-H.;Lee, J.-M.;Hsu, C.-P.;Chen, P.-C.;Lin, C.-W.;Shih, J.-Y.;Yang, P.-C.;Hsiao, C.K.;Lai, L.-C.;Chuang, E.Y.; Lu, T.-P.; Tsai, M.-H.; Lee, J.-M.; Hsu, C.-P.; Chen, P.-C.; Lin, C.-W.; Shih, J.-Y.; Yang, P.-C.; Hsiao, C.K.; Lai, L.-C.; Chuang, E.Y.; ERIC YAO-YU CHUANG |
| 臺大學術典藏 |
2020-04-10T12:51:27Z |
Gefitinib treatment for non-small cell lung cancer - A study including patients with poor performance status
|
Su W.-P.;Yang C.-H.;Yu C.-J.;Shih J.-Y.;Chiun Hsu;Yang P.-C.; Su W.-P.; Yang C.-H.; Yu C.-J.; Shih J.-Y.; Chiun Hsu; Yang P.-C. |
| 臺大學術典藏 |
2020-04-10T12:51:25Z |
Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer
|
Gow C.-H.; Chiun Hsu; Chang G.-C.; Yang P.-C.; Su W.-P.; Lin C.-P.; Yang T.-Y.; Yu C.-J.; Chen K.-C.; Shih J.-Y.; Yang C.-H.; Yang C.-H.;Shih J.-Y.;Chen K.-C.;Yu C.-J.;Yang T.-Y.;Lin C.-P.;Su W.-P.;Gow C.-H.;Chiun Hsu;Chang G.-C.;Yang P.-C. |
| 臺大學術典藏 |
2020-04-10T12:51:22Z |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial
|
Huang T.-C.; Yang P.-C.; Yang C.-H.; Lin C.-C.; Chiun Hsu; Kuo S.-H.; Hu F.-C.; Cheng A.-L.; Shih J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2020-03-31T08:55:00Z |
Sonographic imaging of the trachea
|
Wu H.-D.; Yu C.-J.; Wang H.-C.; Chang Y.-L.; Yang P.-C.; LI-NA LEE; Shih J.-Y. |
| 臺大學術典藏 |
2020-03-31T08:54:37Z |
Coinfection with Mycobacterium tuberculosis and pandemic H1N1 influenza A virus in a patient with lung cancer
|
Tan C.-K.; Kao C.-L.; Shih J.-Y.; LI-NA LEE; Hung C.-C.; Lai C.-C.; Huang Y.-T.; Hsueh P.-R. |
| 臺大學術典藏 |
2020-03-31T03:59:37Z |
Identification of a novel biomarker, SEMA5A, for non-small cell lung carcinoma in nonsmoking women
|
Chuang E.Y.; Lai L.-C.; Hsiao C.K.; Yang P.-C.; Shih J.-Y.; Chen P.-C.; Lin C.-W.; Hsu C.-P.; JANG-MING LEE; Tsai M.-H.; Lu T.-P.; Lu T.-P.;Tsai M.-H.;Jang-Ming Lee;Hsu C.-P.;Chen P.-C.;Lin C.-W.;Shih J.-Y.;Yang P.-C.;Hsiao C.K.;Lai L.-C.;Chuang E.Y. |
| 臺大學術典藏 |
2020-03-30T08:50:55Z |
Comparable clinical outcomes in patients with HER2-mutant and EGFR-mutant lung adenocarcinomas
|
Gow C.-H.;Chang H.-T.;Lim C.-K.;Liu C.-Y.;Jin-Shing Chen;Shih J.-Y.; Gow C.-H.; Chang H.-T.; Lim C.-K.; Liu C.-Y.; JIN-SHING CHEN; Shih J.-Y. |
| 臺大學術典藏 |
2020-03-30T08:50:53Z |
Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib
|
Shih J.-Y.; JIN-SHING CHEN; Lin Z.-Z.; Lin C.-C.; Yang J.C.H.; Yu C.-J.; Yao Z.-H.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Shih J.-Y.;Jin-Shing Chen;Lin Z.-Z.;Lin C.-C.;Yang J.C.H.;Yu C.-J.; Yao Z.-H.; Liao W.-Y.; Ho C.-C.; Chen K.-Y. |
| 臺大學術典藏 |
2020-03-30T08:50:44Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Yu C.-J.; Yang J.C.-H.; Shih J.-Y.; Lin Z.-Z.; Lee J.-H.; Chen K.-Y.; Yang C.-Y.; Hsu C.-L.; Ho C.-C.; Lin Y.-T.;Jin-Shing Chen;Liao W.-Y.;Ho C.-C.;Hsu C.-L.;Yang C.-Y.;Chen K.-Y.;Lee J.-H.;Lin Z.-Z.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.; Lin Y.-T.; JIN-SHING CHEN; Liao W.-Y. |
